New CFO Joins Pasadena’s Axial Biotherapeutics

Published : Tuesday, October 30, 2018 | 7:57 AM

MergerAxial Biotherapeutics, a spin-off tech company holding licensing from Caltech with offices in Boston and Pasadena, announced the hiring a new chief financial officer as well as senior level administrator who will oversee Medical Chemistry.

The company said Jeffrey Young will become its new CFO and Dennis Yasmashita will become its Vice President, Medicinal Chemistry.

Axial’s technology platform was licensed from the Mazmanian Lab at Caltech in Pasadena, California.

Young said he is looking forward to moving Axial’s cutting-edge approach to medicine forward.

“With multiple programs now advancing in and towards the clinic, I look forward to working with this exceptional team toward achieving our next set of milestones and establishing clinical proof of concept for Axial’s breakthrough approach,” Young said.

Young most recently served as CFO, treasurer and secretary at Juniper Pharmaceuticals, Inc., where he played an instrumental role in Juniper’s acquisition by Catalent. Prior, Young served as CFO and treasurer of OvaScience, a global fertility company focused on new treatment options for women.

In addition, he was previously the CFO and treasurer of Transmedics, a developer of medical devices for the maintenance and transport of organs between donors and recipients as well as held numerous other positions. Young holds a Bachelor of Science in Business Administration from Georgetown University.

David H. Donabedian, co-founder and CEO of Axial Biotherapeutics, said Young brings a valuable skill set to Axial.

“Jeff is a highly experienced financial manager with a deep strategic understanding of the field. His addition to our management will greatly help us to continue building the strong financial foundations needed to support our progress in the clinic,” Donabedian, said.

Yamashita is an experienced and accomplished drug developer and medicinal chemist with extensive leadership experience at GSK and in biotech. Prior to joining Axial, Yamashita held various leadership roles at GSK, ORIC, and Trevena.

Most recently, he was VP drug discovery of ORIC (Overcoming Resistance in Cancer) and was formerly VP chemistry at Trevena. At GSK, Yamashita was executive director in Discovery Partnerships with Academia in Cambridge, Massachusetts and was also director of medicinal chemistry in Microbial, Musculoskeletal, and Proliferative Diseases Center of Excellence Drug Discovery in Philadelphia, Pennsylvania.

Yamashita holds a bachelor of science in Chemistry from MIT and a doctorate in Organic Chemistry from Yale University.

blog comments powered by Disqus